NVO Stock Sheds Nearly $50B in Market Cap in a Month: Should You Sell?

Novo Nordisk has erased most of its share gains since the 2021 Wegovy launch after Eli Lilly's GLP‑1 candidates outperformed in clinical studies and put competitive pressure on pricing. Looming price cuts across the core GLP‑1 franchise and stronger clinical data from Lilly create downside risk to Novo’s pricing power and margins, a sector-level negative catalyst likely to move stock-level performance.

Analysis

Novo Nordisk has erased most of its share gains since the 2021 Wegovy launch after Eli Lilly's GLP‑1 candidates outperformed in clinical studies and put competitive pressure on pricing. Looming price cuts across the core GLP‑1 franchise and stronger clinical data from Lilly create downside risk to Novo’s pricing power and margins, a sector-level negative catalyst likely to move stock-level performance.